CUE BIOPHARMA INC (CUE) Stock Earnings & Estimates
NASDAQ:CUE - US22978P1066 - Common Stock
0.8 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.25M -91.63% | 5.49M 339.20% | 9.287M 69.16% | 9.166M -1.30% | 10.1M 10.19% | 20.705M 105.00% | 108.98M 426.35% | 306.33M 181.09% | 14.902M -95.14% | 123.66M 729.82% | 320.77M 159.40% | |
| EBITDA YoY % growth | -52.58M -23.86% | -51.436M 2.18% | -41.196M 19.91% | -54.322M -31.86% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -53.5M -22.40% | -51.992M 2.82% | -41.593M 20.00% | -39.373M 5.34% | -49.389M -25.44% | -44.844M 9.20% | 32.623M 172.75% | 208.77M 539.95% | -96.734M -146.34% | -1.072M 98.89% | 174.06M 16,342.85% | |
| Operating Margin | -4,280.00% | -947.03% | -447.86% | -429.56% | -489.00% | -216.59% | 29.93% | 68.15% | -649.13% | -0.87% | 54.26% | |
| EPS YoY % growth | -1.50 -7.14% | -1.11 26.00% | -0.75 32.43% | -0.55 27.28% | -0.41 25.00% | -0.45 -11.11% | 0.25 155.56% | 1.59 528.00% | -0.46 -129.30% | -0.47 -2.17% | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 31.68% | -0.14 -8.77% | -0.10 43.56% | -0.10 -6.61% | -0.10 13.04% | -0.12 17.86% |
| Revenue Q2Q % growth | 3.032M -9.11% | 2.098M 33.12% | 2.525M 499.76% | 2.525M -14.52% | 2.525M -16.72% | 2.525M 20.35% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.242M 7.52% | -9.425M 2.12% | -11.11M 9.67% | -11.918M -38.02% | -12.625M -53.19% | -13.433M -42.52% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.09 55.00% | -0.14 | 0.05 | 36.35% |
| Q1 2025 Q2Q % growth | -0.17 32.00% | -0.15 | -0.02 | -9.77% |
| Q4 2024 Q2Q % growth | -0.13 55.17% | -0.16 | 0.03 | 17.49% |
| Q3 2024 Q2Q % growth | -0.17 29.17% | -0.19 | 0.02 | 12.56% |
| Q2 2024 Q2Q % growth | -0.20 31.03% | -0.29 | 0.09 | 30.27% |
| Q1 2024 Q2Q % growth | -0.25 13.79% | -0.28 | 0.03 | 12.23% |
| Q4 2023 Q2Q % growth | -0.29 23.68% | -0.28 | -0.01 | -3.28% |
| Q3 2023 Q2Q % growth | -0.24 22.58% | -0.35 | 0.11 | 30.62% |
| Q2 2023 Q2Q % growth | -0.29 21.62% | -0.31 | 0.02 | 5.86% |
| Q1 2023 Q2Q % growth | -0.29 34.09% | -0.29 | 0.00 | 0.99% |
| Q4 2022 Q2Q % growth | -0.38 -52.00% | -0.31 | -0.07 | -21.37% |
| Q3 2022 Q2Q % growth | -0.31 24.39% | -0.38 | 0.07 | 19.23% |
| Q2 2022 Q2Q % growth | -0.37 -12.12% | -0.43 | 0.06 | 13.46% |
| Q1 2022 Q2Q % growth | -0.44 -7.32% | -0.43 | -0.01 | -1.90% |
| Q4 2021 Q2Q % growth | -0.25 30.56% | -0.39 | 0.14 | 35.71% |
| Q3 2021 Q2Q % growth | -0.41 -20.59% | -0.39 | -0.02 | -4.09% |
| Q2 2021 Q2Q % growth | -0.33 13.16% | -0.42 | 0.09 | 21.46% |
| Q1 2021 Q2Q % growth | -0.41 14.58% | -0.38 | -0.03 | -7.39% |
| Q4 2020 Q2Q % growth | -0.36 | -0.35 | -0.01 | -1.84% |
| Q3 2020 Q2Q % growth | -0.34 -9.68% | -0.39 | 0.05 | 12.33% |
| Q2 2020 Q2Q % growth | -0.38 17.39% | -0.43 | 0.05 | 11.68% |
| Q1 2020 Q2Q % growth | -0.48 11.11% | -0.35 | -0.13 | -35.79% |
| Q4 2019 Q2Q % growth | -0.36 | -0.45 | 0.09 | 20.35% |
| Q3 2019 Q2Q % growth | -0.31 | -0.44 | 0.13 | 30.24% |
| Q2 2019 Q2Q % growth | -0.46 | -0.57 | 0.11 | 18.67% |
| Q1 2019 Q2Q % growth | -0.54 | -0.40 | -0.14 | -33.66% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 2.954M 11.14% | 2.419M | 535K | 22.12% |
| Q1 2025 Q2Q % growth | 421K -75.48% | 1.28M | -859K | -67.11% |
| Q4 2024 Q2Q % growth | 1.576M -13.45% | 1.718M | -142K | -8.27% |
| Q3 2024 Q2Q % growth | 3.336M 58.86% | 1.535M | 1.801M | 117.33% |
| Q2 2024 Q2Q % growth | 2.658M 92.33% | 1.302M | 1.356M | 104.15% |
| Q1 2024 Q2Q % growth | 1.717M 818.18% | 1.225M | 492K | 40.16% |
| Q4 2023 Q2Q % growth | 1.821M 1,114.00% | 1.583M | 238K | 15.03% |
| Q3 2023 Q2Q % growth | 2.1M 2,900.00% | 1.144M | 956K | 83.57% |
| Q2 2023 Q2Q % growth | 1.382M 4,506.67% | 916.575K | 465.425K | 50.78% |
| Q1 2023 Q2Q % growth | 187K -81.30% | 1.97M | -1.783M | -90.51% |
| Q4 2022 Q2Q % growth | 150K -98.18% | 104.788K | 45.213K | 43.15% |
| Q3 2022 Q2Q % growth | 70K -97.08% | 444.733K | -374.733K | -84.26% |
| Q2 2022 Q2Q % growth | 30K -98.91% | 1.143M | -1.113M | -97.38% |
| Q1 2022 Q2Q % growth | 1M -35.48% | 3.085M | -2.085M | -67.59% |
| Q4 2021 Q2Q % growth | 8.25M 1,618.75% | 2.996M | 5.254M | 175.37% |
| Q3 2021 Q2Q % growth | 2.4M 242.86% | 1.884M | 516K | 27.39% |
| Q2 2021 Q2Q % growth | 2.74M 153.70% | 1.068M | 1.672M | 156.55% |
| Q1 2021 Q2Q % growth | 1.55M 72.22% | 591.456K | 958.544K | 162.07% |
| Q4 2020 Q2Q % growth | 480K -54.29% | 1.346M | -866K | -64.34% |
| Q3 2020 Q2Q % growth | 700K -28.57% | 1.712M | -1.012M | -59.11% |
| Q2 2020 Q2Q % growth | 1.08M 1.89% | 2.108M | -1.028M | -48.77% |
| Q1 2020 Q2Q % growth | 900K 143.24% | 1.852M | -952K | -51.40% |
| Q4 2019 Q2Q % growth | 1.05M | 881.73K | 168.27K | 19.08% |
| Q3 2019 Q2Q % growth | 980K | 404K | 576K | 142.57% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 11.54% | 13.75% | 8.47% | 5.81% |
| Revenue | 9.1% | 63.63% | 12.38% | 53.38% |